← Back to Search

The CASCADE HF Soft Launch and Calibration Phase I and II

Phase 2 & 3
Waitlist Available
Led By Nirav S Shah, MD, MPH
Research Sponsored by NorthShore University HealthSystem
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 30 days from patient discharge date
Awards & highlights
No Placebo-Only Group

Summary

This trial aims to use a wearable device to monitor patients' health remotely. The device tracks vital signs and sends the information to healthcare providers. This approach helps catch potential health issues early, reducing the chances of patients needing to go back to the hospital.

Eligible Conditions
  • Heart Failure
  • Congestive Heart Failure

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~30 days from patient discharge date
This trial's timeline: 3 weeks for screening, Varies for treatment, and 30 days from patient discharge date for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Attrition Rate
Enrollment Rate
Secondary study objectives
30-day Readmission
Number of Participants With Diuretic Escalation

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: Phase II: Calibration (210 days)Experimental Treatment2 Interventions
After learning from the soft launch and updating the protocol, the study will continue to enroll 15 HF patients for calibration purposes
Group II: Phase I: Soft Launch (120 days)Experimental Treatment2 Interventions
The study will conduct a soft launch on the first five HF patients enrolled to finetune process and protocol.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Non-Invasive Continuous Remote Patient Monitoring
2020
Completed Phase 3
~20

Find a Location

Who is running the clinical trial?

Northwestern UniversityOTHER
1,649 Previous Clinical Trials
958,751 Total Patients Enrolled
22 Trials studying Heart Failure
6,663 Patients Enrolled for Heart Failure
NorthShore University HealthSystemLead Sponsor
132 Previous Clinical Trials
737,622 Total Patients Enrolled
1 Trials studying Heart Failure
43 Patients Enrolled for Heart Failure
physIQ, Inc.Industry Sponsor
3 Previous Clinical Trials
1,530 Total Patients Enrolled
Carnegie Mellon UniversityOTHER
77 Previous Clinical Trials
539,875 Total Patients Enrolled
Nirav S Shah, MD, MPHPrincipal InvestigatorNorthShore University HealthSystem
~4 spots leftby Dec 2025